I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00590096

Enrollment

1380

Registered

2008-01-10

Start date

1991-01-31

Completion date

2008-12-31

Last updated

2009-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma, Pheochromocytoma

Keywords

Neuroblastoma, Pheochromocytoma, MIBG

Brief summary

I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors

Detailed description

Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma. Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide

Interventions

None listed

Study design

Observational model

CASE_ONLY

Eligibility

Sex/Gender

ALL

Age

2 Weeks to No maximum

Healthy volunteers

Inclusion criteria

* Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma

Exclusion criteria

* Pregnancy

Outcome results